Hematocrit Test Devices Market By Product (Automated Hematology Analyzers, Point-of-Care Hematocrit Analyzers, Microhematocrit Centrifuges, Hematocrit Readers, Reagents, Cartridges, and Other Consumables); By Application (Anemia Diagnosis and Monitoring, Kidney Disease and Dialysis Monitoring, Blood Loss and Transfusion Management, Perioperative and Critical-Care Monitoring, Polycythemia and Dehydration Assessment); By End User (Hospitals and Health Systems, Diagnostic and Reference Laboratories, Physician Offices and Point-of-Care Facilities, Dialysis Centers, Blood Banks and Transfusion Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hematocrit Test Devices Market: Bundled CBC Testing, Point-of-Care Consumables, and Dialysis Monitoring Shape Commercial Value

The Global Hematocrit Test Devices Market is valued at USD 5.8 billion in 2025 and is projected to reach USD 8.7 billion by 2032, growing at a CAGR of 6.0%, according to Strategic Market Research. The forecast adds approximately USD 2.9 billion in annual revenue over seven years, supported by routine CBC testing, decentralized diagnostics, recurring consumables, and treatment-linked monitoring.

 

Hematocrit measuring devices determine the percentage of red blood cells in a blood sample through manual separation, direct point-of-care measurement, or automated cell analysis. The commercial device base includes microhematocrit centrifuges and readers, handheld point-of-care analyzers, and comprehensive hematology systems. Each platform serves a different testing environment, ranging from small laboratories and blood banks to emergency departments and centralized hospital laboratories, supporting demand across both capital equipment and recurring consumables.

 

Clinical microhematocrit centrifuges represent the traditional laboratory method. These systems spin blood-filled capillary tubes at speeds of up to 14,000 RPM to separate red blood cells from plasma, after which the packed-cell volume is measured using a graphic reader or an integrated reading scale. The Hettich Haematokrit 200, for example, determines hematocrit in approximately seven minutes. Demand for these systems is supported by their established laboratory use, relatively simple operating requirements, and suitability for facilities that do not require high-throughput automated testing.

 

Handheld point-of-care analyzers compete through faster turnaround, low sample requirements, and decentralized deployment. The CLIA-waived UltraCrit uses ultrasound technology to measure hematocrit from a finger-stick sample, while Nova Biomedical’s StatStrip directly measures hemoglobin and hematocrit in under 40 seconds using 1.6 microliters of blood. In high-volume hospital and reference laboratories, hematocrit is generally reported as part of a complete blood count using automated analyzers based on electrical impedance or flow cytometry. These systems combine hematocrit with broader red-cell, white-cell, and platelet profiles, making market demand dependent on total CBC workloads rather than standalone hematocrit testing alone.

 

Hematocrit Testing Is Embedded in High-Volume Clinical Workflows

Hematocrit measures the proportion of blood occupied by red blood cells and is commonly included in a complete blood count. It supports the evaluation and monitoring of anemia, blood loss, kidney disease, polycythemia, dehydration, transfusion requirements, and perioperative changes in red-cell status. Its market importance comes from the frequency with which it is included in routine and acute-care testing.

Automated laboratory analyzers commonly calculate hematocrit from the red-cell count and average cell volume. Manual microhematocrit systems determine packed-cell volume after centrifugation, while point-of-care platforms may report hematocrit through cartridge-based measurement. Electrical impedance accounted for an estimated 38.10% of 2025 market revenue, equivalent to approximately USD 2.21 billion on the SMR base. Microfluidic and lab-on-chip platforms are projected to expand at a 13.2% CAGR through 2031 as suppliers pursue lower sample requirements and portable testing formats.

Large laboratories purchase automated systems based on CBC workload, reliability, service support, and connectivity. Acute-care departments prioritize rapid results, while smaller laboratories focus on compact equipment and manageable reagent costs. Dialysis providers evaluate hematocrit within broader fluid-management workflows.

 

Anemia Creates the Largest Clinical Demand Base

Anemia is the broadest patient pathway connected to hematocrit testing. During August 2021–August 2023, 9.3% of the U.S. population aged two years or older had anemia. Globally, the Global Burden of Disease 2021 study estimated 1.92 billion prevalent anemia cases, equal to 24.3% of the population across all age groups.

Anemia diagnosis and monitoring accounted for an estimated 59.55% of 2025 hematocrit test device revenue. Applied to the SMR base, the segment generated approximately USD 3.45 billion, making it the largest application area. Commercial demand is supported by repeated CBC testing in primary care, hospitals, maternity services, oncology, nutritional treatment, and chronic-disease follow-up.

Testing frequency varies by diagnosis, treatment stage, access, and care setting. Some patients are tested once, while others receive repeated CBCs during chronic disease management, pregnancy, blood-loss evaluation, or hospitalization. High-volume systems require automated platforms, while lower-resource facilities often use compact analyzers or manual equipment.

 

Kidney Disease and Dialysis Support Predictable Recurring Testing

Kidney disease is one of the most dependable hematocrit-monitoring pathways because impaired kidney function can be associated with reduced red-cell production and repeated blood-count assessment.

CDC estimated that 37 million U.S. adults, or 14% of adults aged 18 and older, had chronic kidney disease. The 2025 USRDS Annual Data Report recorded 831,192 people receiving treatment for end-stage renal disease at the end of 2023. Globally, an estimated 4.59 million people were receiving long-term dialysis or had undergone kidney transplantation in 2023.

As of March 31, 2025, 516,837 patients were receiving dialysis across 7,556 U.S. dialysis centers. This included 433,396 in-center hemodialysis patients, 78,407 home-dialysis patients, and 5,034 patients treated in nursing or skilled-nursing facilities.

Most dialysis patients receive laboratory-based anemia monitoring rather than continuous measurement during every treatment. Dedicated systems combine equipment revenue with session-linked disposable consumption. Dialysis and renal-care applications are projected to expand at a 12.95% CAGR through 2031. Fresenius Medical Care’s Crit-Line platform measures hematocrit, oxygen saturation, and blood-volume change during hemodialysis using a single-use blood chamber.

 

Point-of-Care Testing Competes on Turnaround Time and Workflow

Point-of-care hematocrit devices serve situations in which waiting for a central laboratory result may delay clinical decisions. Demand is concentrated in emergency care, intensive care, operating rooms, neonatal and pediatric units, trauma services, ambulances, and other decentralized settings.

Abbott’s i-STAT cartridges report hematocrit with chemistries, electrolytes, and blood gases, while Siemens Healthineers’ epoc system provides hematocrit within a broader blood-gas and metabolic panel. Hospitals purchase a multi-analyte capability in which hematocrit contributes to the clinical value but does not determine the full investment decision.

Instrument placement depends on result speed, sample requirement, connectivity, quality control, and cost per reportable result. Recurring value lies primarily in proprietary cartridges and test cards. Point-of-care settings are projected to post the fastest end-user CAGR at 13.95% through 2031.

Cost can restrict adoption because cartridge testing may have a higher direct cost than a CBC processed on a high-throughput analyzer. Hospitals therefore reserve point-of-care hematocrit testing for workflows in which speed, patient movement, or immediate decisions justify the added expense.

 

The U.S. Laboratory Network Supports Multiple Device Tiers

CMS recorded 317,545 registered laboratories in its March 2024 CLIA database. These included 244,791 certificate-of-waiver laboratories, 122,451 physician-office laboratories, 9,223 hospital laboratories, 8,474 independent laboratories, 7,247 end-stage renal disease dialysis laboratory sites, 7,080 ambulatory surgery center laboratories, and 422 blood-bank laboratories.

These numbers show the range of purchasing environments. High-throughput platforms are concentrated in hospitals and reference laboratories, while compact analyzers and point-of-care systems serve smaller laboratories, physician practices, rural facilities, blood collection centers, and urgent-care settings.

CLIA requirements influence adoption by linking test complexity to staff qualifications, quality control, proficiency testing, documentation, and laboratory certification. Buyers therefore assess compliance burden alongside equipment and consumable costs.

 

Transfusion and Blood-Bank Activity Adds a Distinct Testing Channel

Hematocrit testing is used around transfusion pathways to assess red-cell status, investigate blood loss, monitor response, and support blood-component quality processes.

The 2023 U.S. National Blood Collection and Utilization Survey reported 11.58 million red-blood-cell units collected and 10.32 million units transfused. WHO reported approximately 120.4 million blood donations worldwide, based mainly on 2023 country data. Only 36% of donations were collected in high-income countries, although those countries represented 15% of the global population, indicating uneven access to collection and testing infrastructure.

Blood banks can use hematology analyzers for pre-donation assessment and component-quality monitoring. Boule Diagnostics positions its Swelab Alfa Plus system for hemoglobin and hematocrit assessment, platelet testing, and red-cell concentrate monitoring. This creates an opportunity for compact platforms serving donor screening and blood-component workflows.

 

Market Segmentation

By Product Type

• Automated hematology analyzers

• Point-of-care and blood-gas analyzers

• Microhematocrit centrifuges

• Hematocrit readers

• Dialysis hematocrit and blood-volume monitors

• Cartridges, reagents, controls, capillary tubes, and disposable blood chambers

Reagents and consumables lead product revenue with a 38.95% share, or about USD 2.26 billion in 2025, because every installed analyzer or meter supports repeated purchases. Hematocrit analyzers are the fastest-growing product group at an estimated 11.92% CAGR through 2031. Automated platforms retain the broadest testing base, while point-of-care cartridges and dialysis disposables generate stronger recurring revenue per installed device.

 

By Testing Environment

• Central laboratories

• Point-of-care and bedside settings

• Physician-office and decentralized laboratories

• Blood banks and donor-testing facilities

• Dialysis centers

• Emergency, perioperative, and critical-care settings

Electrical impedance leads the technology mix with a 38.10% share, equal to approximately USD 2.21 billion in 2025, while microfluidic systems are projected to grow at a 13.2% CAGR through 2031. The shift supports compact analyzers, cartridge-based platforms, and low-sample-volume testing in decentralized environments.

 

By End User

• Hospitals and health systems

• Diagnostic and reference laboratories

• Physician-office laboratories

• Dialysis centers

• Blood banks and transfusion services

• Ambulatory surgery centers

• Emergency and critical-care facilities

Hospitals accounted for an estimated 48.30% of 2025 revenue, equivalent to approximately USD 2.80 billion on the SMR market base. Centralized laboratories, operating rooms, emergency departments, oncology units, and intensive-care services sustain this position. Point-of-care settings are projected to grow at a 13.95% CAGR through 2031, indicating faster expansion in decentralized care than in established central-laboratory environments.

 

Competitive Landscape

The competitive market is divided by workflow rather than by one measurement technology. Sysmex, Beckman Coulter, HORIBA, Mindray, and Boule compete through automated hematology portfolios designed for different laboratory volumes. Abbott and Siemens Healthineers participate through portable cartridge-based blood-analysis systems. Fresenius Medical Care addresses the specialized dialysis-monitoring segment through integrated hematocrit and blood-volume measurement.

Sysmex’s XN-1000 and Beckman Coulter’s DxH 900 serve high-volume laboratories, while Boule and Mindray address smaller facilities. HORIBA’s Yumizen H2500 received FDA 510(k) clearance in 2024. Sysmex was reported to hold 54.6% of the broader automated hematology segment and processed nearly 3 billion CBC tests in 2023, illustrating the advantage of installed instruments and reagent contracts.

Competitive strength is supported by installed analyzer bases, proprietary consumables, information-system connectivity, local service, quality-control support, and broad test menus. Switching platforms can require method comparison, staff training, interface validation, revised quality-control procedures, and new inventory, protecting established suppliers even when competing systems offer lower equipment prices.

 

Regional Market Dynamics

North America represented an estimated 39.20% of global 2025 revenue, equal to approximately USD 2.27 billion on the SMR market base. Its position is supported by hospital, independent-laboratory, physician-office, dialysis, and blood-bank infrastructure, together with analyzer replacement and recurring reagent and cartridge demand.

Europe is characterized by hospital laboratories, regional laboratory networks, decentralized blood-gas testing, and public procurement. Automation, connectivity, tender access, and distributor coverage influence supplier positioning.

Asia-Pacific combines large patient populations with substantial variation in laboratory capacity and is projected to grow at a 13.05% CAGR through 2031, the fastest regional rate. Major urban hospitals support high-throughput automation, while community hospitals and smaller laboratories create demand for compact analyzers, point-of-care meters, and manual systems.

Latin America, the Middle East, and Africa are influenced by hospital investment, blood-bank capacity, distributor coverage, imported consumable costs, and laboratory staffing. Manual microhematocrit systems and compact analyzers retain relevance where advanced automation is difficult to support.

 

Market Growth Drivers

Recurring CBC demand is the central market driver. Routine assessment, chronic-disease management, oncology, kidney care, pregnancy, blood loss, and hospital admissions create repeated hematocrit testing.

Point-of-care expansion supports cartridge consumption in emergency, neonatal, perioperative, and critical-care settings. Growth in dialysis populations increases recurring laboratory monitoring and selected use of treatment-integrated hematocrit systems. Laboratory automation supports replacement of older platforms with systems capable of managing larger sample volumes and reducing manual work. Blood-safety and component-quality requirements add demand from blood banks and transfusion services.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.8 Billion
Revenue Forecast in 2032	USD 8.7 Billion
Overall Growth Rate	CAGR of 6.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Automated Hematology Analyzers, Point-of-Care Hematocrit Analyzers, Microhematocrit Centrifuges, Hematocrit Readers, Reagents, Cartridges, and Other Consumables
By Application	Anemia Diagnosis and Monitoring, Kidney Disease and Dialysis Monitoring, Blood Loss and Transfusion Management, Perioperative and Critical-Care Monitoring, Polycythemia and Dehydration Assessment
By End User	Hospitals and Health Systems, Diagnostic and Reference Laboratories, Physician Offices and Point-of-Care Facilities, Dialysis Centers, Blood Banks and Transfusion Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of anemia and chronic kidney disease; growing demand for rapid point-of-care hematocrit testing; increasing use of hematocrit monitoring in dialysis, critical care, surgery, and transfusion workflows; expansion of automated hematology testing across hospitals and diagnostic laboratories
Customization Option	Available upon request